NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

If it’s good it is just as material, so bad or good, if you were right, it would need to be disclosed immediately

no really not.
Really wonderful you are here freewheeling your thoughts on the subject like a thought exercise, but it is advised to actually do the work and read a lot of literature on the subject and post the relevant parts as I have done over the years. So if you want to convince anyone please dive into the many articles and publications. Let me give you a headstart:

https://www.arnoldporter.com/-/media/files/perspectives/publications/2013/06/predictable-materiality-a-need-for-common-criter__/files/publication/fileattachment/predictablemateriality.pdf?

Finally, beyond the disclosure obligations to the SEC or a company’s shareholders, publicly-listed companies must also provide investors with continuous disclosures of material information pursuant to the rules of the various securities exchanges. For example, the New York Stock Exchange (“NYSE”) Manual requires companies listed on the exchange to “release quickly to the public any news or information which might reasonably be expected to materially affect the market for its securities.”84 It is possible that clinical trial test results for drugs and devices could be considered material “given the enormous costs sunk into research and the high market interest in potential outcomes.

It is too easy to say there is not legislation that applies specifically for NWBO, the legislator/SEC/DOJ did not have NWBO specific in mind when they set out the rules.

https://academic.oup.com/jlb/article/6/1/51/5549623

https://news.bloomberglaw.com/securities-law/insight-the-sec-fda-nexus-best-practices-for-publicly-traded-life-sciences-companies

Good luck reading